___

• 1.Greenhall E, Vessey M. The prevalence of subfertility: a review of the current confusion and a report of two new studies. Fertil Steril 1990;54:978–83. [CrossRef ]
• 2.Jungwirth A, Diemer T, Kopa Z, Krausz C, Minhas S, Tournaye H. EAU Guidelines on Male Infertility. European Association of Urology; 2019. https://uroweb.org/guideline/male-infertility/
• 3.Winters BR, Walsh TJ. The epidemiology of male infertility. Urol Clin North Am 2014;41:195–204. [CrossRef ]
• 4.Smith LB, Walker WH. The regulation of spermatogenesis by androgens. Semin Cell Dev Biol 2014;30:2–13. [CrossRef ]
• 5.Lombardo F, Sgrò P, Salacone P, Gilio B, Gandini L, Dondero F, et al. Androgens and fertility. J Endocrinol Invest 2005;28(3 Suppl):51–5. https://pubmed.ncbi.nlm.nih.gov/16042361/
• 6.Zhang M, Tong G, Liu Y, Mu Y, Weng J, Xue Y, et al. Sequential Versus Continual Purified Urinary FSH/hCG in Men With Idiopathic Hypogonadotropic Hypogonadism. J Clin Endocrinol Metab 2015;100:2449–55. [CrossRef ]
• 7.Vicari E, Mongioì A, Calogero AE, Moncada ML, Sidoti G, Polosa P, d’Agata R. Therapy with human chorionic gonadotrophin alone induces spermatogenesis in men with isolated hypogonadotrophic hypogonadism –long-term follow-up. Int J Androl 1992;15:320–9. [CrossRef ]
• 8.Zacharin M, Sabin MA, Nair VN, Dabadghao P. Addition of recombinant follicle-stimulating hormone to human chorionic gonadotropin treatment in adolescents and young adults with hypogonadotropic hypogonadism promotes normal testicular growth and may promote early spermatogenesis. Fertil Steril 2012;98:836–42. [CrossRef ]
• 9.Bouloux P, Warne DW, Loumaye E; FSH Study Group in Men’s Infertility. Efficacy and safety of recombinant human follicle-stimulating hormone in men with isolated hypogonadotropic hypogonadism. Fertil Steril 2002;77:270–3. [CrossRef ] https://doi.org/10.1016/s0015-0282(01)02973-9
• 10.Milsom S, Duggan K, O’sullivan S, Ogilvie M, Gunn AJ. Treatment of infertility with hypogonadotropic hypogonadism: 10-year experience in Auckland, New Zealand. Aust N Z J Obstet Gynaecol 2012;52:293–8. [CrossRef ]
• 11.Kliesch S, Behre HM, Nieschlag E. High efficacy of gonadotropin or pulsatile gonadotropin-releasing hormone treatment in hypogonadotropic hypogonadal men. Eur J Endocrinol 1994;131:347–54. [CrossRef ]
• 12.Aulitzky W, Frick J, Galvan G. Pulsatile luteinizing hormone-releasing hormone treatment of male hypogonadotropic hypogonadism. Fertil Steril 1988;50:480–6. [CrossRef ]
• 13.Fuse H, Akashi T, Kazama T, Katayama T. Gonadotropin therapy in males with hypogonadotropic hypogonadism: factors affecting induction of spermatogenesis after gonadotropin replacement. Int Urol Nephrol 1996;28:367–74. [CrossRef ]
• 14.Büchter D, Behre HM, Kliesch S, Nieschlag E. Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases. Eur J Endocrinol 1998;139:298–303. [CrossRef ]
• 15.Saa W, Happ J, Cordes U, Baum RP, Schmidt M. Subcutaneous gonadotropin therapy in male patients with hypogonadotropic hypogonadism. Fertil Steril 1991;56:319–24. [CrossRef ]
• 16.Schopohl J. Pulsatile gonadotrophin releasing hormone versus gonadotrophin treatment of hypothalamic hypogonadism in males. Hum Reprod 1993;8 Suppl 2:175–9. [CrossRef ]
• 17.Burris AS, Rodbard HW, Winters SJ, Sherins RJ. Gonadotropin therapy in men with isolated hypogonadotropic hypogonadism: the response to human chorionic gonadotropin is predicted by initial testicular size. J Clin Endocrinol Metab 1988:66:1144–51. [CrossRef ]
• 18.Farhat R, Al-zidjali F, Alzahrani AS. Outcome of gonadotropin therapy for male infertility due to hypogonadotrophic hypogonadism. Pituitary 2010;13:105–10. [CrossRef ]
• 19.Varimo T, Miettinen PJ, Känsäkoski J, Raivio T, Hero M. Congenital hypogonadotropic hypogonadism, functional hypogonadotropism or constitutional delay of growth and puberty? An analysis of a large patient series from a single tertiary center. Hum Reprod 2017;32:147–53. [CrossRef ]
• 20.Nachtigall LB, Boepple PA, Seminara SB, Khoury RH, Sluss PM, Lecain AE, Crowley WF Jr. Inhibin B secretion in males with gonadotropin-releasing hormone (GnRH) deficiency before and during long-term GnRH replacement: relationship to spontaneous puberty, testicular volume, and prior treatment--a clinical research center study. J Clin Endocrinol Metab 1996;81:3520–5. [CrossRef ]
• 21.Matsumoto AM, Snyder PJ, Bhasin S, Martin K, Weber T, Winters S, et al. Stimulation of spermatogenesis with recombinant human follicle-stimulating hormone (follitropin alfa; GONAL-f ): long-term treatment in azoospermic men with hypogonadotropic hypogonadism. Fertil Steril 2009;92:979–90. [CrossRef ]
• 22.Rastrelli G, Corona G, Mannucci E, Maggi M. Factors affecting spermatogenesis upon gonadotropin-replacement therapy: a meta-analytic study. Andrology 2014;2:794–808. [CrossRef ]
• 23.Zhao N, Lu XL, Li JT, Zhang JM. Treatment of idiopathic oligozoospermia with combined human chorionic gonadotropin/human menopausal gonadotrophin: A randomised, double-blinded, placebo-controlled clinical study. Andrologia 2019;51:e13271. [CrossRef ]
• 24.Ruvolo G, Roccheri MC, Brucculeri AM, Longobardi S, Cittadini E, Bosco L. Lower sperm DNA fragmentation after r-FSH administration in functional hypogonadotropic hypogonadism. J Assist Reprod Genet 2013;30:497–503. [CrossRef ]
• 25.Santi D, Granata AR, Simoni M. FSH treatment of male idiopathic infertility improves pregnancy rate: a meta-analysis. Endocr Connect 2015;4:46–58. [CrossRef ]
• 26.Ding YM, Zhang XJ, Li JP, Chen SS, Zhang RT, Tan WL, Shi XJ. Treatment of idiopathic oligozoospermia with recombinant human follicle-stimulating hormone: a prospective, randomized, double-blind, placebo-controlled clinical study in Chinese population. Clin Endocrinol (Oxf ) 2015;83:866–71. [CrossRef ]
• 27.Paradisi R, Natali F, Fabbri R, Battaglia C, Seracchioli R, Venturoli S. Evidence for a stimulatory role of high doses of recombinant human follicle-stimulating hormone in the treatment of male-factor infertility. Andrologia 2014;46:1067–72. [CrossRef ]
• 28.Colacurci N, Monti MG, Fornaro F, Izzo G, Izzo P, Trotta C, et al. Recombinant human FSH reduces sperm DNA fragmentation in men with idiopathic oligoasthenoteratozoospermia. J Androl 2012;33:588–93. [CrossRef ]
• 29.Paradisi R, Busacchi P, Seracchioli R, Porcu E, Venturoli S. Effects of high doses of recombinant human follicle-stimulating hormone in the treatment of male factor infertility: results of a pilot study. Fertil Steril 2006;86:728–31. [CrossRef ]
• 30.Attia AM, Al-Inany HG, Farquhar C, Proctor M. Gonadotrophins for idiopathic male factor subfertility. Cochrane Database Syst Rev 2007;CD005071. [CrossRef ]
• 31.Attia AM, Abou-Setta AM, Al-Inany HG. Gonadotrophins for idiopathic male factor subfertility. Cochrane Database Syst Rev 2013;CD005071. [CrossRef ]
• 32.Oka S, Shiraishi K, Matsuyama H. Effects of human chorionic gonadotropin on testicular interstitial tissues in men with non-obstructive azoospermia. Andrology 2017;5:232–9. [CrossRef ]
• 33.Shinjo E, Shiraishi K, Matsuyama H. The effect of human chorionic gonadotropin-based hormonal therapy on intratesticular testosterone levels and spermatogonial DNA synthesis in men with non-obstructive azoospermia. Andrology 2013;1:929–35. [CrossRef ]
• 34.Roth LW, Ryan AR, Meacham RB. Clomiphene citrate in the management of male infertility. Semin Reprod Med 2013;31:245–50. [CrossRef ]
• 35.Schiff JD, Ramírez ML, Bar-Chama N. Medical and surgical management male infertility. Endocrinol Metab Clin North Am 2007;36:313–31. [CrossRef ]
• 36.Paulson DF. Clomiphene citrate in the management of male hypofertility: predictors for treatment selection. Fertil Steril 1977;28:1226–9. [CrossRef ]
• 37.Mićić S, Dotlić R. Evaluation of sperm parameters in clinical trial with clomiphene citrate of oligospermic men. J Urol 1985;133:221–2. [CrossRef ]
• 38.Sokol RZ, Steiner BS, Bustillo M, Petersen G, Swerdloff RS. A controlled comparison of the efficacy of clomiphene citrate in male infertility. Fertil Steril 1988;49:865–70. [CrossRef ]
• 39.World Health Organization. A double-blind trial of clomiphene citrate for the treatment of idiopathic male infertility. Int J Androl 1992;15:299–307. [CrossRef ]
• 40.Moradi M, Moradi A, Alemi M, Ahmadnia H, Abdi H, Ahmadi A, Bazargan-Hejazi S. Safety and efficacy of clomiphene citrate and L-carnitine in idiopathic male infertility: a comparative study. Urol J 2010;7:188–93. https://journals.sbmu.ac.ir/urolj/index.php/uj/article/view/750/488
• 41.Nada EA, El Taieb MA, Ibrahim HM, Al Saied AE. Efficacy of tamoxifen and l-carnitine on sperm ultrastructure and seminal oxidative stress in patients with idiopathic oligoasthenoteratozoospermia. Andrologia 2015;47:801–10. [CrossRef ]
• 42.Guo L, Jing J, Feng YM, Yao B. Tamoxifen is a potent antioxidant modulator for sperm quality in patients with idiopathic oligoasthenospermia. Int Urol Nephrol 2015;47:1463–9. [CrossRef ]
• 43.Patankar SS, Kaore SB, Sawane MV, Mishra NV, Deshkar AM. Effect of clomiphene citrate on sperm density in male partners of infertile couples. Indian J Physiol Pharmacol 2007;51:195–8. https://pubmed.ncbi.nlm.nih.gov/18175667/
• 44.Vandekerckhove P, Lilford R, Vail A, Hughes E, Hafez M. Clomiphene or tamoxifen for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev 2007;CD000151. [CrossRef ]
• 45.Chua ME, Escusa KG, Luna S, Tapia LC, Dofitas B, Morales M. Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis. Andrology 2013;1:749–57. [CrossRef ]
• 46.Ghanem H, Shaeer O, El-Segini A. Combination clomiphene citrate and antioxidant therapy for idiopathic male infertility: a randomized controlled trial. Fertil Steril 2010;93:2232–5. [CrossRef ]
• 47.ElSheikh MG, Hosny MB, Elshenoufy A, Elghamrawi H, Fayad A, Abdelrahman S. Combination of vitamin E and clomiphene citrate in treating patients with idiopathic oligoasthenozoospermia: A prospective, randomized trial. Andrology 2015;3:864–7. [CrossRef ]
• 48.Adamopoulos DA, Pappa A, Billa E, Nicopoulou S, Koukkou E, Michopoulos J. Effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in men with idiopathic oligozoospermia. Fertil Steril 2003;80:914–20. [CrossRef ]
• 49.Tang KF, Zhao YL, Ding SS, Wu QF, Wang XY, Shi JQ, et al. Genetic polymorphisms of CYP2D6*10 and the effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in infertile men with idiopathic oligozoospermia. J Zhejiang Univ Sci B 2015;16:191–7. [CrossRef ]
• 50.Hussein A, Ozgok Y, Ross L, Niederberger C. Clomiphene administration for cases of nonobstructive azoospermia: a multicenter study. J Androl 2005;26:787–91. [CrossRef ]
• 51.Moein MR, Tabibnejad N, Ghasemzadeh J. Beneficial effect of tamoxifen on sperm recovery in infertile men with nonobstructive azoospermia. Andrologia 2012;44 Suppl 1:194–8. [CrossRef ]
• 52.Schlegel PN. Aromatase inhibitors for male infertility. Fertil Steril 2012;98:1359–62. [CrossRef ]
• 53.Mitwally MF, Casper RF. Aromatase inhibitors for the treatment of infertility. Expert Opin Investig Drugs 2003;12:353–71. [CrossRef ]
• 54. Clark RV, Sherins RJ. Treatment of men with idiopathic oligozoospermic infertility using the aromatase inhibitor, testolactone. Results of a double-blinded, randomized, placebo-controlled trial with crossover. J Androl 1989;10:240–7. [CrossRef ]
• 55.Roth MY, Amory JK, Page ST. Treatment of male infertility secondary to morbid obesity. Nat Clin Pract Endocrinol Metab 2008;4:415–9. [CrossRef ]
• 56.Saylam B, Efesoy O, Cayan S. The effect of aromatase inhibitor letrozole on body mass index, serum hormones, and sperm parameters in infertile men. Fertil Steril 2011;95:809–11. [CrossRef ]
• 57.Gregoriou O, Bakas P, Grigoriadis C, Creatsa M, Hassiakos D, Creatsas G. Changes in hormonal profile and seminal parameters with use of aromatase inhibitors in management of infertile men with low testosterone to estradiol ratios. Fertil Steril 2012;98:48–51. [CrossRef ]
• 58.Cavallini G, Biagiotti G, Bolzon E. Multivariate analysis to predict letrozole efficacy in improving sperm count of non-obstructive azoospermic and cryptozoospermic patients: a pilot study. Asian J Androl 2013;15:806–11. [CrossRef ]
• 59.Cavallini G, Beretta G, Biagiotti G. Preliminary study of letrozole use for improving spermatogenesis in non-obstructive azoospermia patients with normal serum FSH. Asian J Androl 2011;13:895–7. [CrossRef ]
• 60.Ramasamy R, Ricci JA, Palermo GD, Gosden LV, Rosenwaks Z, Schlegel PN. Successful fertility treatment for Klinefelter’s syndrome. J Urol 2009;182:1108–13. [CrossRef ]
• 61. Shuling L, Kuei MLS, Saffari SE, Jiayun Z, Yeun TT, Leng JPW, et al. Do men with normal testosterone-oestradiol ratios benefit from letrozole for the treatment of male infertility? Reprod Biomed 2019;38:39–45. [CrossRef ]
• 62.Birch N, Shaw M. Retrograde ejaculation after anterior lumbar interbody fusion. Spine (Phila Pa 1976) 2004;29:106–7. [CrossRef ]
• 63.Ellenberg M, Weber H. Retrograde ejaculation in diabetic neuropathy. Ann Intern Med 1966;65:1237–46. [CrossRef ]
• 64. Yavetz H, Yogev L, Hauser R, Lessing JB, Paz G, Homonnai ZT. Retrograde ejaculation. Hum Reprod 1994;9:381–6. [CrossRef ]
• 65. Shoshany O, Abhyankar N, Elyaguov J, Niederberger C. Efficacy of treatment with pseudoephedrine in men with retrograde ejaculation. Andrology 2017;5:744–8. [CrossRef ]
• 66.Soler JM, Previnaire JG, Plante P, Denys P, Chartier-Kastler E. Midodrine improves ejaculation in spinal cord injured men. J Urol 2007;178:2082–6. [CrossRef ]
• 67.Ichiyanagi O, Sasagawa I, Suzuki Y, Matsuki S, Itoh K, Miura M, Tomita Y. Successful treatment of retrograde ejaculation with amezinium. Arch Androl 2003;49:215–7. [CrossRef ]
• 68.Ebner T, Shebl O, Mayer RB, Moser M, Costamoling W, Oppelt P. Healthy live birth using theophylline in a case of retrograde ejaculation and absolute asthenozoospermia. Fertil Steril 2014;101:340–3.[CrossRef ]
• 69.Hu J, Nagao K, Tai T, Kobayashi H, Nakajima K. Randomized Crossover Trial of Amoxapine Versus Vitamin B12 for Retrograde Ejaculation. Int Braz J Urol 2017;43:496–504. [CrossRef ]
• 70.Arafa M, Tabie OE. Medical treatment of retrograde ejaculation in diabetic patients: a hope for spontaneous pregnancy. J Sex Med 2008;5:194–8. [CrossRef ]
• 71.Pujianto DA, Curry BJ, Aitken RJ. Prolactin exerts a prosurvival effect on human spermatozoa via mechanisms that involve the stimulation of Akt phosphorylation and suppression of caspase activation and capacitation. Endocrinology 2010;151:1269–79. [CrossRef ]
• 72. Sueldo CE, Berger T, Kletzky O, Marrs RP. Seminal prolactin concentration and sperm reproductive capacity. Fertil Steril 1985;43:632–5. [CrossRef ]
• 73.Nishimura K, Matsumiya K, Tsuboniwa N, Yamanaka M, Koga M, Miura H, Tsujimura A. Bromocriptine for infertile males with mild hyperprolactinemia: hormonal and spermatogenic effects. Arch Androl 1999;43:207–13. [CrossRef ]
• 74. Kawano M, Yasumoto R, Tsujino T, Masuda C, Sakakura T, Nishisaka N, Kishimoto T. A case of oligozoospermia with marginal hyperprolactinemia due to pituitary microadenoma. Hinyokika Kiyo 1996;42:319–21. https://repository.kulib.kyoto-u.ac.jp/dspace/handle/2433/115702
• 75.Saie DJ, Sills ES. Hyperprolactinemia presenting with encephalomalacia-associated seizure disorder and infertility: a novel application for bromocriptine therapy in reproductive endocrinology. Neuro Endocrinol Lett 2005;26:533–5. https://pubmed.ncbi.nlm.nih.gov/16264405/
• 76. De Rosa M, Ciccarelli A, Zarrilli S, Guerra E, Gaccione M, Di Sarno A, et al. The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. Clin Endocrinol (Oxf ) 2006;64:307–13. [CrossRef ]
• 77.De Rosa M, Colao A, Di Sarno A, Ferone D, Landi ML, Zarrilli S, et al. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol 1998;138:286–93. [CrossRef ]
• 78.Schuppe HC, Pilatz A, Hossain H, Diemer T, Wagenlehner F, Weidner W. Urogenital Infection as a Risk Factor for Male Infertility. Dtsch Arztebl Int 2017;114:339–46. [CrossRef ]
• 79.Cunningham KA, Beagley KW. Male genital tract chlamydial infection: implications for pathology and infertility. Biol Reprod 2008;79:180–9. [CrossRef ]
• 80.Alshahrani S, McGill J, Agarwal A. Prostatitis and male infertility. J Reprod Immunol 2013;100:30–6. [CrossRef ]
• 81.Purvis K, Christiansen E. Infection in the male reproductive tract. Impact, diagnosis and treatment in relation to male infertility. Int J Androl 1993;16:1–13. [CrossRef ]
• 82. Tremellen K. Oxidative stress and male infertility –a clinical perspective. Hum Reprod Update 2008;14:243–58. [CrossRef ]
• 83.Custo GM, Lauro V, Saitto C, Frongillo RF. Chlamydial infection and male infertility: an epidemiological study. Arch Androl 1989;23:243–8. [CrossRef ]
• 84. Zhang L, Zhang KP, Liang CZ. Ureaplasma urealyticum in male genital tract: a hidden risk factor for male infertility. Andrologia 2016;48:1077–9. [CrossRef ]
• 85.Beeton ML, Payne MS, Jones L. The Role of Ureaplasma spp. in the Development of Nongonococcal Urethritis and Infertility among Men. Clin Microbiol Rev 2019;32:e00137–18. [CrossRef ]
• 86.Pajovic B, Radojevic N, Vukovic M, Stjepcevic A. Semen analysis before and after antibiotic treatment of asymptomatic Chlamydia- and Ureaplasma-related pyospermia. Andrologia 2013;45:266–71. [CrossRef ]
• 87.Branigan EF, Muller CH. Efficacy of treatment and recurrence rate of leukocytospermia in infertile men with prostatitis. Fertil Steril 1994;62:580–4. [CrossRef ]
• 88.Yamamoto M, Hibi H, Katsuno S, Miyake K. Antibiotic and ejaculation treatments improve resolution rate of leukocytospermia in infertile men with prostatitis. Nagoya J Med Sci 1995;58:41–5. https://pubmed.ncbi.nlm.nih.gov/7659146/
• 89.Lackner JE, Lakovic E, Waldhör T, Schatzl G, Marberger M. Spontaneous variation of leukocytospermia in asymptomatic infertile males. Fertil Steril 2008;90:1757–60. [CrossRef ]
• 90.Vicari E. Effectiveness and limits of antimicrobial treatment on seminal leukocyte concentration and related reactive oxygen species production in patients with male accessory gland infection. Hum Reprod 2000;15:2536–44. [CrossRef ]
• 91.Gambera L, Serafini F, Morgante G, Focarelli R, De Leo V, Piomboni P. Sperm quality and pregnancy rate after COX-2 inhibitor therapy of infertile males with abacterial leukocytospermia. Hum Reprod 2007;22:1047–51. [CrossRef ]
• 92. Agarwal A, Rana M, Qiu E, AlBunni H, Bui AD, Henkel R. Role of oxidative stress, infection and inflammation in male infertility. Andrologia 2018;50:e13126. [CrossRef ]
• 93. Aitken RJ, Smith TB, Jobling MS, Baker MA, De Iuliis GN. Oxidative stress and male reproductive health. Asian J Androl 2014;16:31–8. [CrossRef ]
• 94. Atan A, Polat F, Yeşil S, Ünsal A. Erkek infertilitesinin medikal tedavisi. Yeni Üroloji Derg 2017;12:58–62. https://dergipark.org.tr/tr/download/article-file/658739
• 95.Mayorga-Torres BJM, Camargo M, Cadavid ÁP, du Plessis SS, Cardona Maya WD. Are oxidative stress markers associated with unexplained male infertility? Andrologia 2017;49:e12659. [CrossRef ]
• 96.Saleh RA, Agarwal A, Nada EA, El-Tonsy MH, Sharma RK, Meyer A, et al. Negative effects of increased sperm DNA damage in relation to seminal oxidative stress in men with idiopathic and male factor infertility. Fertil Steril 2003;79:1597–605. [CrossRef ]
• 97.Sikka SC, Rajasekaran M, Hellstrom WJ. Role of oxidative stress and antioxidants in male infertility. J Androl 1995;16:464–8. https://onlinelibrary.wiley.com/doi/abs/10.1002/j.1939-4640.1995.tb00566.x?sid=nlm%3Apubmed
• 98.Huang C, Cao X, Pang D, Li C, Luo Q, Zou Y, et al. Is male infertility associated with increased oxidative stress in seminal plasma? A-meta analysis. Oncotarget 2018;9:24494–513. [CrossRef ]
• 99.Beigi Harchegani A, Dahan H, Tahmasbpour E, Bakhtiari Kaboutaraki H, Shahriary A. Effects of zinc deficiency on impaired spermatogenesis and male infertility: the role of oxidative stress, inflammation and apoptosis. Hum Fertil (Camb) 2020;23:5–16. [CrossRef ]
• 100.Buhling K, Schumacher A, Eulenburg CZ, Laakmann E. Influence of oral vitamin and mineral supplementation on male infertility: a meta-analysis and systematic review. Reprod Biomed 2019;39:269–79. [CrossRef ]
• 101.Nazari L, Salehpour S, Hosseini S, Allameh F, Jahanmardi F, Azizi E, et al. Effect of antioxidant supplementation containing L-carnitine on semen parameters: a prospective interventional study. JBRA Assist Reprod 2021;25:76–80. [CrossRef ]
• 102.Mancini A, Balercia G. Coenzyme Q(10) in male infertility: physiopathology and therapy. Biofactors 2011;37:374–80. [CrossRef ]
• 103.Greco E, Iacobelli M, Rienzi L, Ubaldi F, Ferrero S, Tesarik J. Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment. J Androl 2005;26:349–53. [CrossRef ]
• 104.Sharma RK, Agarwal A. Role of reactive oxygen species in male infertility. Urology 1996;48:835–50. [CrossRef ]
• 105.Micic S, Lalic N, Djordjevic D, Bojanic N, Bogavac-Stanojevic N, Busetto GM, et al. Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia 2019;51:e13267. [CrossRef ]
• 106.Lenzi A, Sgrò P, Salacone P, Paoli D, Gilio B, Lombardo F, et al. A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia. Fertil Steril 2004;81:1578–84. [CrossRef ]
• 107.Sigman M, Glass S, Campagnone J, Pryor JL. Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertil Steril 2006;85(5):1409-14. [CrossRef ]
• 108.Balercia G, Regoli F, Armeni T, Koverech A, Mantero F, Boscaro M. Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertil Steril 2005;84:662–71. [CrossRef ]
• 109.Galimov ShN, Gromenko DS, Galimova ÉF, Gromenko II, Iskhakov IR. Effects of L-carnitine on ejaculate parameters in males from infertile couples. Urologiia 2012;(1):47–51. https://pubmed.ncbi.nlm.nih.gov/22646002/
• 110.Zhou X, Liu F, Zhai S. Effect of L-carnitine and/or L-acetyl-carnitine in nutrition treatment for male infertility: a systematic review. Asia Pac J Clin Nutr 2007;16 Suppl 1:383–90. https://pubmed.ncbi.nlm.nih.gov/17392136/
• 111.Nadjarzadeh A, Sadeghi MR, Amirjannati N, Vafa MR, Motevalian SA, Gohari MR, et al. Coenzyme Q10 improves seminal oxidative defense but does not affect on semen parameters in idiopathic oligoasthenoteratozoospermia: a randomized double-blind, placebo controlled trial. J Endocrinol Invest 2011;34:e224–8. [CrossRef ]
• 112.Tang KF, Xing Y, Wu CY, Liu RZ, Wang XY, Xing JP. Tamoxifen combined with coenzyme Q10 for idiopathic oligoasthenospermia. Zhonghua Nan Ke Xue 2011;17:615–8. https://pubmed.ncbi.nlm.nih.gov/21823344/
• 113.Safarinejad MR. The effect of coenzyme Q10 supplementation on partner pregnancy rate in infertile men with idiopathic oligoasthenoteratozoospermia: an open-label prospective study. Int Urol Nephrol 2012;44:689–700. [CrossRef ]
• 114.Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S. Effects of the reduced form of coenzyme Q10(ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. J Urol 2012;188:526–31. [CrossRef ]
• 115.Lafuente R, González-Comadrán M, Solà I, López G, Brassesco M, Carreras R, Checa MA. Coenzyme Q10 and male infertility: a meta-analysis. J Assist Reprod Genet 2013;30:1147–56. [CrossRef ]
• 116.Smits RM, Mackenzie-Proctor R, Yazdani A, Stankiewicz MT, Jordan V, Showell MG. Antioxidants for male subfertility. Cochrane Database Syst Rev 2019;3:CD007411. [CrossRef ]
• 117.Ross C, Morriss A, Khairy M, Khalaf Y, Braude P, Coomarasamy A, El-Toukhy T. A systematic review of the effect of oral antioxidants on male infertility. Reprod Biomed 2010;20:711–23. [CrossRef ]
• 118.Sofimajidpour H, Ghaderi E, Ganji O. Comparison of the Effects of Varicocelectomy and Oral L-carnitine on Sperm Parameters in Infertile Men with Varicocele. J Clin Diagn Res 2016;10: PC07–10. [CrossRef ]
• 119.Ener K, Aldemir M, Işık E, Okulu E, Özcan MF, Uğurlu M, et al. The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia 2016;48:829–34. [CrossRef ]
• 120.Barekat F, Tavalaee M, Deemeh MR, Bahreinian M, Azadi L, Abbasi H, et al. A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. Int J Fertil Steril 2016;10:120–6. [CrossRef ]